帕拉丁科技公司公布了其口服MC4R激动剂PL7737在肥胖动物模型中的积极临床前疗效数据。研究显示,PL7737与替西帕肽联用产生附加减肥效果,口服给药后在短短四天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药研究申请(IND),为后续开发铺路。
帕拉丁科技公司公布了其口服MC4R激动剂PL7737在肥胖动物模型中的积极临床前疗效数据。研究显示,PL7737与替西帕肽联用产生附加减肥效果,口服给药后在短短四天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药研究申请(IND),为后续开发铺路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.